Study guide

9.2 Atrial Fibrillation & Atrial Flutter: Classification, ECG Recognition & Stroke Risk

Registered Cardiac Electrophysiology Specialist RCES

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pre-Procedural Assessment & Patient Preparation

1.1 Procedure Room Preparation, Equipment Verification & Aseptic Readiness 1.2 Pre-Procedural Clinical Evaluation, Labs, Consents & The Universal Time-Out 1.3 Patient Identification, Transport, HIPAA & Procedural Documentation 1.4 Patient Monitoring Setup, Defibrillator Pads & Pre-Procedural CIED Interrogation 1.5 Vascular Access Planning, Skin Preparation & Sterile Draping

2 Chapter 2: Cardiac Anatomy, Conduction & Electrophysiologic Foundations

2.1 Cardiac Anatomy for the EP Lab: Chambers, Access Routes & Coronary Supply 2.2 The Cardiac Conduction System, Action Potentials & Ion Channel Physiology 2.3 Cardiac Vector Analysis, 12-Lead ECG Fundamentals & Axis Determination

3 Chapter 3: EP Lab Instrumentation, Connectology & Lab Safety

3.1 EP Recording System Architecture, Signal Amplification & Frequency Filters 3.2 Cardiac Stimulator Operation, Junction Box Routing & Noise Troubleshooting 3.3 Electrical Safety, Electrical Units, Electrocautery & Fire Safety 3.4 Radiation Safety Physics, ALARA Principles, Shielding & Dose Limits 3.5 Procedural Supplies, Catheter Inventory, Surgical Instrumentation & Wound Closure

4 Chapter 4: Intra-Procedural Imaging, Sedation & Physiologic Monitoring

4.1 Fluoroscopic Projections (RAO, LAO, AP) & X-ray Tube Optimization 4.2 Intracardiac Echocardiography (ICE) Principles, Views & Catheter Navigation 4.3 Non-Radiographic Imaging: Cardiac CT/MRI, Image Fusion & Ultrasound-Guided Access 4.4 Conscious Sedation Protocols, Airway Management & Hemodynamic Monitoring 4.5 Vital Signs, Normal Laboratory Values & Intra-Procedural Lab Monitoring

5 Chapter 5: EP Pharmacology, Anticoagulation & Emergency Drugs

5.1 Vaughan Williams Antiarrhythmic Classification & EP Electrophysiology 5.2 Diagnostic & Provocative Drugs: Adenosine, Isoproterenol, Epinephrine, Atropine 5.3 Sedation & Analgesia Pharmacology, Reversal Agents & Recovery Scoring 5.4 Heparin Protocol, ACT Monitoring & Emergency Reversal with Protamine 5.5 Oral Anticoagulants, Antiplatelets & Peri-Procedural Management 5.6 ACLS Algorithms & Emergency Medications in the EP Lab

6 Chapter 6: Catheter Navigation, Normal Electrograms & Baseline Intervals

6.1 Standard Diagnostic Catheter Positions & Fluoroscopic/Anatomical Landmarks 6.2 Intracardiac Electrogram Interpretation & Normal Baseline Intervals (PA, AH, HV) 6.3 His Bundle Electrogram Recording, Split His Potentials & Infranodal Conduction

7 Chapter 7: Programmed Electrical Stimulation & Refractory Periods

7.1 Pacing Stimulation Fundamentals, Capture Thresholds & Drive Trains 7.2 Refractory Period Determination (ERP, RRP, FRP) & Sinus Node Function Testing (SNRT, cSNRT) 7.3 AV Nodal Decremental Conduction & Dual AV Nodal Physiology

8 Chapter 8: Diagnostic Evaluation of Supraventricular & Ventricular Tachycardias

8.1 Narrow-Complex Tachycardias: Differential Diagnosis of AVNRT, AVRT & AT 8.2 Diagnostic Pacing Maneuvers: Entrainment, PPI-TCL, V-A-V vs V-A-A-V & His-Refractory PVCs 8.3 Wide-Complex Tachycardias & Ventricular Arrhythmia Mapping Criteria

9 Chapter 9: Bradyarrhythmias, AV Block & Atrial Arrhythmia Recognition

9.1 Bradyarrhythmias, AV Block Classification & Conduction System Disease 9.2 Atrial Fibrillation & Atrial Flutter: Classification, ECG Recognition & Stroke Risk

10 Chapter 10: 3D Electroanatomic Mapping & Ablation Biophysics

10.1 3D Electroanatomic Mapping Systems (Carto, EnSite, Rhythmia) Setup & Troubleshooting 10.2 Activation, Propagation & Bipolar Voltage Substrate Mapping 10.3 Ablation Biophysics: Radiofrequency, Cryoablation & Pulsed Field Ablation (PFA)

11 Chapter 11: Transseptal Access, Catheter Ablation Targets & Endpoints

11.1 Transseptal Puncture: Anatomy, Technique, Imaging Guidance & Complications 11.2 Catheter Ablation of AVNRT Slow Pathway & Accessory Pathways (WPW) 11.3 Cavotricuspid Isthmus (CTI) Ablation for Typical Atrial Flutter 11.4 Pulmonary Vein Isolation (PVI) for AFib & Ventricular Tachycardia Ablation

12 Chapter 12: Cardiac Implantable Electronic Devices: Implantation & Testing

12.1 Pacemaker & Transvenous ICD Implantation Techniques & Safety 12.2 Intra-Procedural Electrical Testing: Sensing, Pacing Thresholds, Impedance & DFT 12.3 Cardiac Resynchronization Therapy (CRT) & Conduction System Pacing (HBP, LBBAP)

13 Chapter 13: CIED Interrogation, Programming & Troubleshooting

13.1 NBG Pacemaker Codes, Pacing Modes & Timing Cycles 13.2 CIED Interrogation Workflow, Programmer Operation & Peri-Procedural Reprogramming 13.3 Interpreting & Conveying Interrogated Data: Diagnostics, Counters & Stored Episodes 13.4 Pacing & Sensing Malfunctions, Electromagnetic Interference & Temporary Pacing

14 Chapter 14: Specialized Devices, Extraction & Acute Procedural Emergencies

14.1 Subcutaneous ICD (S-ICD), Leadless Pacemakers & Left Atrial Appendage Closure 14.2 Transvenous Lead Extraction Tools, Techniques & Safety Precautions 14.3 Acute Procedural Emergencies: Perforation, Tamponade, Pericardiocentesis & Air Embolism

15 Chapter 15: Post-Procedural Care, Hemostasis & Complication Management

15.1 Femoral Hemostasis Techniques: Manual Compression, Figure-of-8 & Closure Devices 15.2 Post-Procedural Complications: Vascular Injury, AV Block, Esophageal Injury & Neurologic Deficits 15.3 Post-Procedural CIED Assessment, Device Follow-Up & Wound Care 15.4 Post-Procedure Patient Recovery, Discharge Education & Clinical Handover

9.2 Atrial Fibrillation & Atrial Flutter: Classification, ECG Recognition & Stroke Risk

Key Takeaways Explain This Topic AI

Atrial fibrillation shows no discrete P waves and an irregularly irregular ventricular response; typical atrial flutter shows sawtooth waves at about 250-350 beats per minute.

Counterclockwise typical flutter produces negative sawtooth waves in II, III, and aVF with a positive flutter wave in V1; clockwise flutter reverses both.

AF classification is paroxysmal (terminates within 7 days), persistent (over 7 days), long-standing persistent (over 12 months), and permanent (a decision to stop rhythm control).

Ectopy from myocardial sleeves in the pulmonary veins triggers most paroxysmal atrial fibrillation, which is why pulmonary vein isolation is the cornerstone ablation.

Irregularly irregular wide complexes at rates above 250 beats per minute with varying QRS morphology indicate pre-excited atrial fibrillation and prohibit AV nodal blocking drugs.

Last updated: September 2026

9.2 Atrial Fibrillation & Atrial Flutter: Classification, ECG Recognition & Stroke Risk

Atrial fibrillation is the most common sustained arrhythmia in adults and the reason most EP labs are busy. CCI tests it through ECG/EGM rhythm analysis and interpretation , cardiac pathophysiology , and indications for ablation procedures in the knowledge list, and through tasks C4 and D2-D4.

1. Atrial Fibrillation on the ECG

  • Feature Finding
  • P waves Absent — replaced by chaotic fibrillatory (f) waves at 400-600/min
  • Ventricular response Irregularly irregular , classically 100-180 bpm untreated
  • QRS Narrow unless aberrancy, bundle branch block, or pre-excitation
  • Baseline Coarse or fine undulation; fine AF can look deceptively flat

Irregular irregularity with no discernible P waves is the diagnosis. Two mimics must be excluded: multifocal atrial tachycardia (irregular but with ≥ 3 distinct P-wave morphologies and measurable PR intervals) and atrial flutter with variable block (irregular but with organized, constant-rate flutter waves).

Ashman phenomenon describes an aberrantly conducted beat following a long-short RR sequence — the long cycle lengthens refractoriness, so the next early beat finds the right bundle refractory and conducts with an RBBB pattern. It is a benign functional phenomenon, not ventricular ectopy.

An entirely regular ventricular response during known atrial fibrillation is abnormal and means either complete AV block with a junctional or ventricular escape (classically digoxin toxicity ) or a paced/regularized rhythm.

2. Atrial Flutter

Atrial flutter is a macroreentrant atrial tachycardia — a wavefront circulating around an anatomic obstacle with an excitable gap — which is exactly why it can be entrained and ablated with a line.

Typical (cavotricuspid isthmus-dependent) flutter

The circuit runs around the tricuspid annulus, constrained anteriorly by the annulus and posteriorly by the crista terminalis and Eustachian ridge, passing through the cavotricuspid isthmus between the tricuspid annulus and the inferior vena cava.

  • Counterclockwise (typical, ~90%) Clockwise (reverse typical)
  • Circuit direction (LAO view) Counterclockwise around the tricuspid annulus Clockwise
  • Leads II, III, aVF Negative sawtooth flutter waves Positive , broader flutter waves
  • Lead V1 Positive (upright) flutter wave Negative
  • Septal activation Caudocranial (up the septum) Craniocaudal
  • Atrial rate ~250-350 bpm (typically ~300) Same

Because the atrial rate is near 300 with 2:1 AV conduction, the classic presentation is a regular narrow-complex tachycardia at almost exactly 150 bpm — the single most useful pattern-recognition cue in bedside EP. Any regular narrow tachycardia at 150 should prompt a hunt for flutter waves, using vagal maneuvers or adenosine to increase AV block and unmask them.

Both directions use the same isthmus, so both are cured by the same cavotricuspid isthmus line .

Atypical flutter

Any macroreentrant atrial tachycardia not dependent on the cavotricuspid isthmus: peri-mitral flutter around the mitral annulus, roof-dependent left atrial flutter, scar-related circuits after cardiac surgery or prior ablation, and upper-loop right atrial reentry. Atypical flutter is common after atrial fibrillation ablation because prior lesion sets create the required barriers, and it requires activation and entrainment mapping to define the circuit rather than a standard anatomic line.

3. Classification and Pathophysiology of Atrial Fibrillation

  • Category Definition
  • Paroxysmal Terminates spontaneously or with intervention within 7 days of onset
  • Persistent Sustained beyond 7 days
  • Long-standing persistent Continuous for more than 12 months with a rhythm-control strategy still pursued

Permanent A joint clinical decision to stop pursuing sinus rhythm — a decision, not an electrophysiologic state

Note that permanent AF is defined by intent, not by the arrhythmia , and reclassifies if the decision changes. Contemporary staging frameworks also recognize risk-factor and pre-clinical stages preceding clinical AF, reflecting the shift toward treating obesity, sleep apnea, alcohol use, hypertension, and deconditioning as part of rhythm management.

Mechanism. Two components combine:

Triggers — rapidly firing ectopic foci, most arising from myocardial sleeves extending from the left atrium into the pulmonary veins , longest in the superior veins. This is the observation that created pulmonary vein isolation. Non-pulmonary-vein triggers include the superior vena cava, coronary sinus, ligament of Marshall, crista terminalis, and left atrial appendage.

Substrate — atrial stretch, fibrosis, inflammation, and shortened refractoriness that let multiple wavelets or rotors sustain the arrhythmia. AF begets AF : electrical and structural remodeling from ongoing fibrillation makes subsequent episodes easier to sustain, which is the rationale for early rhythm control.

Consequences: loss of the atrial contribution to filling (roughly 20-30% of cardiac output, worst in a stiff ventricle), stasis in the left atrial appendage producing thromboembolism, and tachycardia-induced cardiomyopathy with poorly controlled rates.

4. Management Framework

Rate control targets a resting ventricular rate typically below 110 bpm in an asymptomatic patient (lenient) or below 80 bpm when symptoms persist (strict), using beta blockers, non-dihydropyridine calcium channel blockers, or digoxin — with the caveat that digoxin's vagal mechanism fails during exertion.

Rhythm control uses antiarrhythmic drugs, cardioversion, or catheter ablation. Trial evidence supports early rhythm control in recently diagnosed AF, and catheter ablation is superior to antiarrhythmic drugs for maintaining sinus rhythm, particularly in paroxysmal AF and in AF with heart failure and reduced ejection fraction , where ablation improves outcomes.

Cardioversion timing and anticoagulation is a rule-based area the exam favors:

  • Scenario Requirement
  • AF < 48 h duration, low risk Cardiovert with anticoagulation started at presentation

AF ≥ 48 h or unknown duration 3 weeks of therapeutic anticoagulation before , or a TEE to exclude appendage thrombus , then cardiovert

  • Any cardioversion ≥ 4 weeks of anticoagulation afterward because of atrial stunning
  • Hemodynamic instability Cardiovert immediately, anticoagulate as soon as feasible

AV junction ablation with pacing ("ablate and pace") is the last-resort rate-control strategy for refractory symptomatic AF: the AV junction is ablated deliberately, creating permanent complete heart block, and the patient becomes absolutely pacemaker-dependent . It controls rate and regularizes the rhythm but does not eliminate atrial fibrillation or the need for anticoagulation.

5. Pre-Excited Atrial Fibrillation — the Emergency

When atrial fibrillation occurs in a patient with a manifest accessory pathway, the pathway's non-decremental, fast-response conduction transmits the chaotic atrial rate directly to the ventricle.

Recognition:

  • Irregularly irregular rhythm
  • Wide QRS complexes with varying morphology (fusion between pathway and AV nodal conduction beat to beat)

Very rapid rate, often 250-300+ bpm , with the shortest pre-excited RR interval being the key risk marker (≤ 250 ms indicates a high-risk pathway)

Management:

  • Do Never
  • Immediate synchronized cardioversion if unstable Adenosine
  • Procainamide or ibutilide if stable Verapamil or diltiazem
  • Prompt referral for accessory pathway ablation Digoxin
  • Beta blockers (AV nodal blockade)
  • Amiodarone IV (AV nodal effect; now avoided in this setting)

The mechanism of harm is uniform: every prohibited agent blocks the AV node, removing the only limiting pathway and channelling the entire atrial rate down the accessory pathway, accelerating the ventricular response into ventricular fibrillation . This single scenario appears on nearly every EP-oriented certification exam, and the correct instinct is to reach for cardioversion or a sodium channel blocker rather than for the familiar rate-control drugs.